Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Bolt Biotherapeutics Inc BOLT

Healthcare Biotechnology
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform... see more

Current News (NDAQ:BOLT)

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 12, 2025

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

GlobeNewswire October 1, 2025

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 14, 2025

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire May 12, 2025

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

GlobeNewswire May 8, 2025

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody(TM) ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

GlobeNewswire April 30, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

GlobeNewswire April 25, 2025

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

GlobeNewswire March 25, 2025

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

GlobeNewswire March 24, 2025
View More News ››

Opinion & Analysis (NDAQ:BOLT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:BOLT)

Is bolt a good buy?

What the opinion out there?
Tulsa123 - January 8, 2025

BOLT Completes NI 43-101 Report for Switchback Property—Reso

Bolt Metals has wrapped up its NI 43-101 technical report for the Switchback Copper-Silver Property. This milestone could pave the way...
TradeVanguard27 - November 27, 2024

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT): Pivoting to a Focu

http://beyondspx.com/2024/08/02/bolt-biotherapeutics-inc-nasdaqbolt-pivoting-to-a-focused-pipeline-and-streamlined-operations-to-maximize...
MikeTester - August 3, 2024
View more Bullboard ››

Lipari Mining Ltd.

Lipari Mining Ltd.

Lipari Mining is a natural diamond producer from its 100% owned Braúna diamond mine in Brazil. The Braúna mine is the only ...
View More »

Podcasts